Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study
Open Access
- 18 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 22 (3), 394-404
- https://doi.org/10.1007/s10165-011-0525-5
Abstract
We (JMAAV [Japanese patients with MPO-ANCA-associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis. Patients with MPO-ANCA-associated vasculitis received a severity-based regimen according to the appropriate protocol: low-dose corticosteroid and, if necessary, cyclophosphamide or azathioprine in patients with mild form; high-dose corticosteroid and cyclophosphamide in those with severe form; and the severe-form regimen plus plasmapheresis in those with the most severe form. We followed up the patients for 18 months. The primary end points were the induction of remission, death, and end-stage renal disease (ESRD). Fifty-two patients were registered, and 48 patients were enrolled in this study (mild form, n = 23; severe form, n = 23; most severe form, n = 2). Among the 47 patients who received the predefined therapies, 42 achieved remission within 6 months, 5 died, and 1 developed ESRD. Disease flared up in 8 of the 42 patients with remission during the 18-month follow-up period. The JMAAV trial is the first prospective trial for MPO-ANCA-associated vasculitis to be performed in Japan. The remission and death rates were comparable to those in several previous clinical trials performed in western counties. The regimen employed in this trial was tailor-made based on patients’ disease severity and disease type, and it seems that standardization can be consistent with treatment choices made according to severity.Keywords
This publication has 19 references indexed in Scilit:
- Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosisAnnals Of The Rheumatic Diseases, 2011
- Development of comprehensive disease assessment in systemic vasculitis.2006
- Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2005
- A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic AutoantibodiesThe New England Journal of Medicine, 2003
- Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitidesArthritis & Rheumatism, 1997
- Prognostic Factors in Polyarteritis Nodosa and Churg-Strauss Syndrome A Prospective Study in 342 PatientsMedicine, 1996
- Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies?Clinical and Experimental Immunology, 1995
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- Anti-Neutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase in Patients with Systemic Vasculitis and Idiopathic Necrotizing and Crescentic GlomerulonephritisThe New England Journal of Medicine, 1988
- AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSISThe Lancet, 1985